Drug Profile
Sodium thiosulfate - Hope Pharmaceuticals
Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Hope Pharmaceuticals
- Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
- Mechanism of Action Antioxidants; Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Chemotherapy-induced damage
- Phase III Calciphylaxis
Most Recent Events
- 25 Jul 2022 No development reported - Phase-III for Calciphylaxis in United Kingdom (IV)
- 15 May 2020 Hope Pharmaceuticals terminates a phase-III CALISTA clinical trial in Calciphylaxis in Canada, in the UK and USA (IV) (NCT03150420)
- 27 Jun 2019 Phase-III clinical trials in Calciphylaxis in United Kingdom (IV)